South Korean digital therapeutics startup Nunaps has closed a ₩5 billion ($4.2 million) funding round.
➨ Company K Partners, KTB Network and K2 Investment Partners provided the funding
➨ Nunaps recently conducted a clinical trial of Nunap Vision
➨ The product provides visual perception training via VR to treat visual field defects caused by brain damage
Company K Partners, KTB Network and K2 Investment Partners provided the funding, which Nunaps intends to invest in digital therapeutics platforms to treat neurological disorders.
The startup’s launch product, Nunap Vision, runs on a virtual reality (VR) hardware and utilises the in-house expertise of neurologists, software and game/VR developers, engineers, artificial intelligence (AI) scientists, perceptual psychologists, and mathematicians.
Nunaps recently conducted a clinical trial of Nunap Vision, which provides visual perception training to treat visual field defects caused by brain damage. The startup said it was the first digital therapeutics trial approved by South Korea’s healthcare regulator, the Ministry of Food and Drug Safety.
Launched in 2017, Nunaps has three neurologists at the helm. Founder and chief executive officer Dong-Wha Kang said he launched the startup because he wanted to develop a new therapy with clinical and practical applications for patients who suffer from visual field defects.
He said: “They have had no effective treatment until now. In our efforts to treat patients with unmet needs, we naturally came up with digital.”
Kang-Soo Lee, chief investment officer at Company K Partners, said: “Nunaps is Korea’s first digital therapeutics company and has great potential to become a global top-tier, setting up clinical trials for new digital therapeutics that employs AI technologies to address neurological disorders.”
Nunaps plans to develop pipelines for various brain disorders in the next few years. Kang said: “It is vital to carry out patient-centered R&D for the developed products to be put into practical use. We will develop super-customised digital therapeutics so that patients may directly experience our products and be empowered to engage in our development.”
Image credit: Nunaps